KRAS and intrahepatic cholangiocarcinoma: In intrahepatic cholangiocarcinoma, the second most common primary hepatic malignancy, the presence of a high-risk gene signature, which includes alterations in TP53, KRAS, or CDK2NA, has been associated with a worse OS in patients treated with medicine, surgery, or TARE [39,40].